<i id='96E67E0C80'><strike id='96E67E0C80'><tt id='96E67E0C80'><pre id='96E67E0C80'></pre></tt></strike></i> 
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
Alkermes shareholders re 
David Ricks of Eli Lilly: best biopharma CEO of 2023 
Jerome Adams on the need for new antivirals for Covid 
Virtual care provider acquires bankrupt Pear's prescription apps 
Duchenne breakthrough therapy leaves behind pioneering families 
Study: Hearing aids may slow cognitive decline in those at risk 
How one medical school became remarkably diverse 
Drinking less cuts risk of oral cavity, esophageal cancer: Report 
Medicare proposal to cover medical devices draws a mixed reaction 
Flagship, Pfizer team up in deal worth up to $7 billion 
Anesthesiologist group: stop taking Ozempic before surgery 
Why health care costs have stayed mostly flat since 2010 
Moonlake's readout produced a cash windfall. Risks remain 
Israeli protesters block highways, train stations as Netanyahu moves ahead with judicial overhaul 
Medicare details structure of new drug price negotiation program 
